-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, V7wx/cbr8bLS5xhOQmG9+lQzeHAFFcy56NbAjEXQ6lqpf4M/HTzzRJB2tRstDjbS RF17/1IrUwFCqxY+l8bciw== 0001275287-05-000707.txt : 20050224 0001275287-05-000707.hdr.sgml : 20050224 20050224093141 ACCESSION NUMBER: 0001275287-05-000707 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20050224 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20050224 DATE AS OF CHANGE: 20050224 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ROCKWELL MEDICAL TECHNOLOGIES INC CENTRAL INDEX KEY: 0001041024 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 383317208 STATE OF INCORPORATION: MI FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-23661 FILM NUMBER: 05635922 BUSINESS ADDRESS: STREET 1: 30142 S WIXOM RD CITY: WIXOM STATE: MI ZIP: 48393 BUSINESS PHONE: 2489609009 MAIL ADDRESS: STREET 1: 30142 S WIXOM RD CITY: WIXOM STATE: MI ZIP: 48393 8-K 1 rm2128.txt ================================================================================ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 24, 2005 ROCKWELL MEDICAL TECHNOLOGIES, INC. -------------------------------------------------------- (Exact name of registrant as specified in its Charter) Michigan 000-230-661 38-3317208 ---------------------------- ------------- ------------------ (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) 30142 Wixom Road, Michigan 48334 ---------------------------------------- ---------- (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code (248) 960-9009 Not applicable --------------------------------------------------------------- (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): [ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) ================================================================================ ITEM 7.01 REGULATION FD DISCLOSURE. On February 24, 2005, the Company issued a press release describing its entry into a lease for a manufacturing and distribution facility in South Carolina. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference. ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS (c) EXHIBITS. The following exhibit is filed with this Form 8-K: Exhibit Description ------- -------------------------------------------------------------- 99.1 Press release, dated February 24, 2005, issued by Rockwell Medical Technologies, Inc. 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ROCKWELL MEDICAL TECHNOLOGIES, INC. Date: February 24, 2005 By: /s/ Robert L. Chioini ------------------------------ Robert L. Chioini President and Chief Executive Officer 3 EXHIBIT INDEX Exhibit Description - ------- ---------------------------------------------------------------------- 99.1 Press release, dated February 24, 2005, issued by Rockwell Medical Technologies, Inc. 4 EX-99.1 2 rm2128ex991.txt EXHIBIT 99.1 ROCKWELL MEDICAL TECHNOLOGIES, INC. ADDS MANUFACTURING AND DISTRIBUTION OPERATION IN THE SOUTHEAST U.S. WIXOM, Mich., Feb. 24 /PRNewswire-FirstCall/ -- Rockwell Medical Technologies Inc. (Nasdaq: RMTI), a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, announced today that it has leased a turn-key concentrate manufacturing facility in South Carolina. This is the Company's third regional production facility which now includes the Midwest (MI), Southwest (TX) and Southeast (SC). Located in Hodges, South Carolina the 61,000 square foot facility is expected to be fully operational by the end of the first quarter and will service both existing and new customers in the region. The Company anticipates shifting existing Southeast business currently serviced from its Michigan and Texas plants to the South Carolina plant. The Company believes a Southeast facility will reduce distribution costs in the Southeast region. This leased manufacturing facility provides the Company with an interim Southeastern presence while it evaluates the potential to establish a long- term Southeastern regional facility. In the fourth quarter of 2004, the Company added substantial business in the Southeastern region. In addition, on February 15, 2005, Rockwell announced that it had signed multiple concentrate supply contracts in the Southeastern region. In the aggregate, the new business in the Southeast calls for Rockwell to supply dialysis concentrate to approximately 12,000 patients in 160 clinics. Mr. Robert L. Chioini, Chairman, CEO and President of Rockwell, stated, "Based on the substantial growth we have experienced in the Southeast during the fourth quarter of 2004 and this first quarter of 2005, coupled with our strategic expansion initiative, we have added production and distribution resources to address that growth. We recognize the need to establish a presence in the Southeast and now we are well positioned to service those customer's needs as well as gain a greater presence in the dialysis provider market in that region." Rockwell Medical Technologies, Inc. is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products that improve the quality of care for dialysis patients. Dialysis is a process that duplicates kidney function for those patients whose kidneys have failed to work properly and suffer from chronic kidney failure, a condition also known as end stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream. Rockwell offers the proprietary Dri- Sate(R) Dry Acid Mixing System, RenalPure(TM) Liquid Acid, RenalPure(TM) Powder Bicarbonate, SteriLyte(R) Liquid Bicarbonate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items. Visit Rockwell's website at http://www.rockwellmed.com. Certain statements in this press release with respect to Rockwell's business and operations, including the statements regarding the Company's anticipated sales revenue, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect management's expectations and are based upon currently available information. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based upon reasonable assumptions. However, certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties. SOURCE Rockwell Medical Technologies, Inc. -0- 02/24/2005 /CONTACT: Thomas Klema of Rockwell Medical Technologies, Inc., +1-248-449-3353/ /Web site: http://www.rockwellmed.com / - - -----END PRIVACY-ENHANCED MESSAGE-----